UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549




FORM			8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~April 7~~May 4, 2022

QUIDEL CORPORATION

(Exact name of Registrant as specified in its Charter)


Delaware	0-10961	94-2573850
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9975 Summers Ridge Road, San Diego, California 92121

(Address of principal executive offices, including zip code)

(858) 552-1100

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

☐☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.12a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 Par Value	QDEL	The Nasdaq Stock Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.			☐

Item 2.02 Results of Operations and Financial Condition.

On May 4, 2022, Quidel Corporation (the "Company") issued a press release announcing ~~its~~the ~~preliminary~~financial ~~revenue~~ results for ~~the~~its first quarter ended March 31, 2022 onand ~~April~~will 7hold an earnings conference call at 2:00 p.m., Pacific Time, on May 4, 2022 to discuss such results. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K.

The information in this current report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section. The information in this current report on Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished with this current report on Form 8-K:

Exhibit Number

Description of Exhibit

99.1

Press release, dated May 4, 2022, reporting Quidel Corporation's financial results for its first quarter ended March 31, 2022.

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.

(d) Exhibits.

The following exhibit is furnished with this current report on Form 8-K:

Exhibit Number

Description of Exhibit

99.1

Press release, dated April 7, 2022

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document

Where You Can Find Additional Information

In connection with the proposed business combination transaction among the Company, Ortho Clinical Diagnostics Holdings plc (“Ortho”) and Coronado Topco, Inc. (“Topco”), Topco has filed a registration statement on Form S-4 (File No. 333-262434) with the Securities and Exchange Commission (the “Commission”) that contains a definitive joint proxy statement/prospectus and other relevant documents concerning the proposed transaction. The registration statement, as amended, was declared effective by the Commission on April 11, 2022. Each of the Company and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of the Company and Ortho, respectively, on or about April 11, 2022. The Company and Ortho may also file other documents with the Commission regarding the proposed transaction. This communication is not a substitute for the joint proxy statement/prospectus or registration statement or for any other document that the Company and Ortho have filed or may file with the Commission in connection with the proposed transaction. YOU ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND THE OTHER RELEVANT DOCUMENTS FILED WITH THE COMMISSION (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, ORTHO AND THE PROPOSED TRANSACTION. The joint proxy statement/prospectus ~~will be mailed to the Company’s stockholders~~ and ~~Ortho’s shareholders when available. The joint proxy statement/prospectus and~~ the other documents filed with the Commission may ~~also~~ be obtained free of charge at the Commission’s website, www.sec.gov. In addition, you may obtain free copies of the joint proxy statement/prospectus and the other documents filed by the Company and Ortho with the Commission by requesting them in writing from Quidel Corporation, 9975 Summers Ridge Road, San Diego, California 92121, Attention: Investor Relations, or by telephone at 858-646-8023, or from Ortho Clinical Diagnostics Holdings plc, 1001 Route 202, Raritan, New Jersey 08869, Attention: Investor Relations, or by directing a written request to SVC Ortho-SVC@SARDVERB.com.

The Company and Ortho and their respective directors and executive officers may be deemed under the rules of the Commission to be participants in the solicitation of proxies. Information about the Company’s directors and executive officers and their ownership of the Company’s common stock is set forth in the joint proxy statement/prospectus. Information about Ortho’s directors and executive officers and their ownership of Ortho’s ordinary shares is also set forth in the joint proxy statement/prospectus. The joint proxy statement/prospectus may be obtained free of charge from the sources indicated above. Information regarding the identity of the potential participants, and their direct or indirect interests in the transaction, by security holdings or otherwise, is included in the joint proxy statement/prospectus, which constitutes a part of the registration statement on Form S-4 filed by Topco with the Commission, as amended from time to time. Stockholders may obtain additional information about the interests of the directors and executive officers in the proposed transaction by reading the joint proxy statement/prospectus and other relevant materials filed with the Commission.

Forward-Looking Statements

This ~~press~~document ~~release~~ contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements and other forward-looking statements in this ~~press~~document ~~release~~ by words such as “may”,” “will”,” “would”,” “expect”,” “anticipate”,” “believe”,” “estimate”,” “plan”,” “intend”,” “continue”,” or similar words, expressions or the negative of such terms or other comparable terminology. These statements include, but are not limited to, ~~our~~the ~~estimated~~benefits ~~revenues~~of ~~for~~the business combination transaction involving the ~~first~~Company, ~~quarter~~Ortho ofand ~~2022~~Topco, including the combined company’s future financial and operating results, plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of the Company’s and Ortho’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the ~~current~~forward-looking ~~beliefs~~statements: the evolution of the COVID-19 pandemic and ~~expectations~~its impact; competition; our development of new technologies, products, and markets; our reliance on sales of our COVID-19 and influenza diagnostic tests; our reliance on a limited number of key distributors; acceptance of our products among physicians, healthcare providers, or other customers; the ~~Company’s~~impact of third-party reimbursement policies; our ability to meet demand for our products; interruptions in our supply of raw materials and ~~Ortho’s~~other ~~management~~product and ~~are~~production ~~subject~~components; costs and disruptions from failures in our information technology and storage systems; international risks, including compliance with product registration requirements and legal requirements, tariffs, currency exchange fluctuations, reduced protection of intellectual property rights, and taxes; worldwide economic, political, and social uncertainty; our development, acquisition, and protection of proprietary technology rights; intellectual property risks and third-party claims of infringement; loss of our Emergency Use Authorization from the U.S. Food and Drug Administration for our COVID-19 products; failures or delays in receiving regulatory approvals, clearances, or authorizations, the loss of previously received approvals, or other adverse actions by regulatory authorities; performance, timing, funding and compliance risks relating to ~~significant~~government contracts; product defects; compliance with government regulations relating to the handling, storage, and disposal of hazardous substances; our ability to identify and successfully acquire and integrate potential acquisition targets; our need for additional funds to finance our capital or operating needs; failure to complete the proposed business combination transaction with Ortho on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory and stockholder approvals, the sanction of the High Court of Justice of England and Wales and satisfaction of other closing conditions to consummate the proposed transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed business combination transaction; the challenges and costs of closing, integrating, restructuring and achieving anticipated synergies; the ability to retain key employees; and other economic, business, competitive, and/or regulatory factors affecting the businesses of the Company and Ortho generally. ~~Actual~~Additional ~~results~~risks ~~may~~and ~~differ~~factors ~~from~~are ~~those~~identified ~~set~~under ~~forth~~“Risk Factors” in the ~~forward~~joint proxy statement/prospectus and in the Company's Annual Report on Form 10-~~looking~~K ~~statements~~filed on February 18, 2022 and subsequent reports filed with the Commission.

~~The~~You ~~following~~should ~~factors,~~not ~~among~~rely ~~others,~~upon ~~could cause actual results to differ from those set forth in the~~ forward-looking statements: ~~the~~as ~~evolution~~predictions of ~~the~~future ~~COVID-19~~events ~~pandemic~~because ~~and~~these ~~its~~statements ~~impact;~~are ~~competition;~~based ~~our~~on ~~development~~assumptions ofthat ~~new~~may ~~technologies,~~not ~~products,~~come ~~and~~true ~~markets; our reliance on sales of our COVID-19~~ and ~~influenza~~are ~~diagnostic~~speculative ~~tests;~~by ~~our~~their ~~reliance~~nature. onNeither ~~a limited number of key distributors; acceptance of our products among physicians, healthcare providers, or other customers;~~ the ~~impact~~Company ofnor ~~third-party~~Ortho ~~reimbursement~~undertakes ~~policies;~~an ~~our~~obligation ~~ability~~ to ~~meet~~update ~~demand~~any ~~for our products; interruptions in our supply~~ of raw materials and other product and production components; costs and disruptions from failures in our information technology and storage systems; international risks, including compliance with product registration requirements and legal requirements, tariffs, currency exchange fluctuations, reduced protection of intellectual property rights, and taxes; worldwide economic, political, and social uncertainty; our development, acquisition, and protection of proprietary technology rights; intellectual property risks and third-party claims of infringement; loss of our Emergency Use Authorization from the ~~U.S. Food and Drug Administration for our COVID~~forward-19looking ~~products;~~information ~~failures~~included ~~or delays~~ in ~~receiving~~this ~~regulatory approvals~~document, ~~clearances,~~whether oras ~~authorizations,~~a ~~the~~result ~~loss~~ of ~~previously~~new ~~received approvals~~information, orfuture ~~other adverse actions by regulatory authorities; performance~~events, ~~timing,~~changed ~~funding~~expectations and compliance risks relating to government contracts; product defects; compliance with government regulations relating to the handling, storage, and disposal of hazardous substances; our ability to identify and successfully acquire and integrate potential acquisition targets; our need for additional funds to finance our capital or ~~operating needs; failure to complete the proposed business combination transaction on the proposed terms or on the anticipated timeline~~otherwise, orexcept atas ~~all,~~required ~~including~~by risks and uncertainties related to securing the necessary regulatory and stockholder approvals, the sanction of the High Court of Justice of England and Wales and satisfaction of other closing conditions to consummate the proposed transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed business combination transaction; the challenges and costs of closing, integrating, restructuring and achieving anticipated synergies; the ability to retain key employees; and other economic, business, competitive, and/or regulatory factors affecting the businesses of the Company and Ortho generallylaw. Additional risks and factors are identified under “Risk Factors” in the joint proxy statement/prospectus and the Company’s Annual Report on Form 10-K filed on February 18, 2022 and subsequent reports filed with the Commission.

You should not rely upon forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. Neither the Company nor Ortho undertakes an obligation to update any of the forward-looking information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

The City Code on Takeovers and Mergers

The City Code on Takeovers and Mergers does not apply to the proposed business combination.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 4, 2022

Date: April 7, 2022





QUIDEL CORPORATION

By:			/s/ Randall J. Steward
Name:			Randall J. Steward
Its:			Chief Financial Officer

Filing Compare · QUIDEL CORP /DE/